MFC
Financials
Valuation Metrics
MFC's Market Cap is ₩223B. At end of 2025 it was ₩300B. Ranked #2248 of 2,436 in KR market (top 92%), #1477 of 1,649 on KOSDAQ (top 90%), #226 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 97%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 22.34B KRW | KR#2,248/2,436 Sec#226/234 |
| Revenue | 18.11B KRW | KR#2,163/2,436 Sec#159/234 |
| Net Income | 224.4M KRW | KR#1,490/2,436 Sec#104/234 |
| Total Assets | 34.43B KRW | KR#2,301/2,436 Sec#216/234 |
| Net Assets | 29.49B KRW | KR#2,170/2,436 Sec#193/234 |
| Employees | 70 | KR#1,853/2,436 Sec#158/234 |
| Value | ||
| P/E | 99.57x | KR#1,437/2,436 Sec#95/234 |
| P/B | 0.76x | KR#1,224/2,436 Sec#69/234 |
| P/S | 1.23x | KR#1,530/2,436 Sec#89/234 |
| Profitability | ||
| ROE | 0.76% | KR#1,441/2,436 Sec#99/234 |
| ROA | 0.65% | KR#1,386/2,436 Sec#98/234 |
| Op. Margin | -0.87% | KR#1,671/2,436 Sec#118/234 |
| Revenue Growth | -45.78% | KR#2,264/2,436 Sec#201/234 |
| Earnings Growth | -1850.85% | KR#1,719/2,436 Sec#119/234 |
| Financial Health | ||
| Debt Ratio | 116.75% | KR#585/2,436 Sec#76/234 |
| Total Debt | 2.83B KRW | KR#1,868/2,436 Sec#179/234 |
| Cash | 3.64B KRW | KR#2,100/2,436 Sec#194/234 |
| Current Ratio | 3.83x | KR#445/2,436 Sec#74/234 |
| Performance | ||
| 1Y Return | -35.56% | KR#1,724/2,436 Sec#152/234 |
| 1M Return | -9.09% | KR#1,702/2,436 Sec#170/234 |
| From 52W High | -42.60% | KR#877/2,436 Sec#62/234 |
| 1Y MDD | -41.64% | KR#577/2,436 Sec#43/234 |
| Trading | ||
| Volume | 1,969 shares | KR#2,347/2,436 Sec#229/234 |
| Foreign Own. | 1.36% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | 26 KRW | KR#1,484/2,436 Sec#104/234 |
| BPS | 3,652 KRW | KR#1,683/2,436 Sec#128/234 |
Company Info
MFC, established in 2008, is a specialized company in Active Pharmaceutical Ingredient (API) and material development and manufacturing, listed on the KOSDAQ market as a technology growth company in 2024. Utilizing organic synthesis, mass production, and new crystallization technologies, MFC develops and mass produces APIs, Key Starting Materials (KSM), and Pharmaceutical Intermediates (PI). The company produces and sells APIs for various therapeutic areas, including cardiovascular, digestive, and anti-inflammatory and analgesic treatments. MFC is pursuing market preemption by securing intellectual property rights for new crystal forms and salts in the improved new drug raw materials sector. The company is headquartered in Hwaseong-si, Gyeonggi-do.